Table 3.

Univariate analysis for overall survival and local control

Covariate categories	N	OS (%)		p	LC (%)		p
		3 years	5 years		3 years	5 years
Age, years
> 70	24	25.0 ± 8.8	16.7 ± 7.6	0.57	64.2 ± 4.7	64.2 ± 5.9	0.71
< 70	37	35.1 ± 7.8	18.9 ± 6.4		82.3 ± 4.4	82.3 ± 5.6
Gender
Male	35	20.6 ± 6.9	11.8 ± 5.5	0.01	78.1 ± 4.3	78.1 ± 5.4	0.97
Female	26	44.4 ± 9.6	25.9 ± 8.4		81.8 ± 4.1	81.8 ± 5.4
Cancer type
Colorectal	29	41.1 ± 7.5	27.3 ± 8.1	< 0.001	75.3 ± 4.7	75.3 ± 5.7	0.47
Breast cancer	11	33.0 ± 7.3	20.1 ± 6.9		86.8 ± 4.8	86.8 ± 5.7
Gynecological cancer	7	56.8 ± 6.9	27.8 ± 7.3		86.1 ± 4.7	86.1 ± 5.6
Other	14	10.2 ± 7.2	–		80.0 ± 4.4	–
Number of metastases
1	48	42.8 ± 13.2	28.6 ± 12.1	0.22	82.0 ± 4.5	82.0 ± 5.4	0.28
2–3	13	27.7 ± 6.5	14.9 ± 5.2		67.3 ± 4.7	67.3 ± 5.6
Size of metastases
< 3 cm	32	28.1 ± 7.9	15.6 ± 6.4	0.46	77.2 ± 4.3	77.2 ± 5.5	0.60
> 3 cm	29	34.4 ± 8.8	20.7 ± 7.5		81.9 ± 4.3	81.9 ± 5.9
Timing of metastasis
Synchronous	24	29.3 ± 6.5	17.0 ± 5.5	0.93	–		–
Metachronous	37	32.2 ± 8.1	19.3 ± 6.9
Time since diagnosis, mo
≤ 12	35	31.4 ± 7.8	17.1 ± 6.4	0.91	–		–
> 12	26	30.8 ± 9.0	19.2 ± 7.7
Prior local therapy
Yes	27	33.3 ± 9.1	11.1 ± 6.1	0.54	65.8 ± 4.6	66.7 ± 5.7	0.06
No	34	29.4 ± 7.8	23.5 ± 7.3		87.1 ± 4.8	87.1 ± 5.8
Pre-SBRT chemotherapy
0–1 schedule	23	43.5 ± 10.3	30.4 ± 9.6	0.10	–		–
2–3-4 schedules	38	23.7 ± 6.9	10.5 ± 5.0
Extrahepatic disease
Yes	21	33.3 ± 10.3	14.3 ± 7.6	0.88	–		–
No	40	30.0 ± 7.2	20.0 ± 6.3